Telix, Regeneron partner to develop next-generation radiopharmaceutical cancer therapies

• Telix entered radiopharma collaboration with Regeneron to co-develop, manufacture, and commercialize next-generation radiopharmaceutical therapies.
• Agreement uses 50/50 cost- and profit-sharing model for global commercialization, with Telix option to co-promote selected products.
• Regeneron will pay Telix USD 40 million upfront for four initial therapeutic programs, with option to add four more programs for additional upfront payments.
• Telix can opt out of co-funding per program, triggering eligibility for up to USD 535 million in milestones and low double-digit royalties for that program.
• Parties will also co-develop diagnostic assets, with Telix leading commercialization and Regeneron receiving profit share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 13, 2026, and is solely responsible for the information contained therein.